Pulse Biosciences' nPulse Cardiac Catheter Shows Strong Efficacy in Atrial Fibrillation Study — Pulse Biosciences, Inc.

Event summary

Pulse Biosciences presented late-breaking data from its nPulse Cardiac Catheter first-in-human feasibility study at the AF Symposium, showing 100% procedural success at 6 months and 96% at one year.
The study treated 150 patients with rapid procedure times (65 ± 28 minutes) and minimal adverse effects (1.3% SAE rate).
Key investigators included Dr. Vivek Reddy at Mount Sinai Fuster Heart Hospital and Dr. Andrea Natale at Tor Vergata Hospital.
The ongoing feasibility study has treated a total of 165 patients across nine investigators in Europe.

The big picture

Pulse Biosciences' nPulse Cardiac Catheter represents a potential disruptive innovation in the treatment of atrial fibrillation, offering a non-thermal ablation approach that could improve procedural efficiency and patient outcomes. The strong feasibility study results position the company to challenge existing technologies in the cardiac ablation market, which is driven by the growing prevalence of atrial fibrillation and the need for more effective and safer treatment options.

What we're watching

Regulatory Approval: The pace at which Pulse Biosciences can secure regulatory approval for the nPulse Cardiac Catheter in the U.S. and Europe, following the promising feasibility study results.
Market Adoption: Whether the differentiated energy and workflow of the nPulse system will drive significant market adoption among electrophysiologists treating atrial fibrillation.
Competitive Positioning: How Pulse Biosciences positions itself against established players in the cardiac ablation market, leveraging its non-thermal nsPFA technology.